Exhaustive Study Guide: Acute Kidney Injury and Chronic Kidney Disease

Overview of Renal Impairment: AKI vs. CKD

• Clinical Settings and Context:

  • Acute Kidney Injury (AKI) is most commonly encountered in acute care settings and represents a sudden disruption in renal function that can either be temporary or progress to Chronic Kidney Disease (CKD).

  • Chronic Kidney Disease (CKD) is predominantly managed in community-based settings or exists as a coexisting chronic condition in hospitalized acute care patients.

• Renal Replacement Therapy and Quality of Life:

  • Both conditions may require renal replacement therapy, such as dialysis or kidney transplantation.

  • For End-Stage Renal Disease (ESRD) or severe CKD, dialysis or transplantation serves as a life-saving intervention necessary to maintain physiological homeostasis and correct acid-base balance.

  • Chronic kidney disease significantly reduces the patient's long-term quality of life and lifespan, requiring adherence to a complex medical regimen.

Acute Kidney Injury (AKI): Diagnostic Criteria and Pathophysiology

• Definition of AKI:

  • An abrupt or rapid decline in renal filtration function occurring over hours to days.

• Diagnostic Criteria (Diagnostic Thresholds):

  • Diagnosed when at least one of the following three criteria is present:

  • An increase in serum creatinine concentration by $0.3\,mg/dL$ or more within a $48\text{-hour}$ window.

  • An increase in serum creatinine to $1.5 \times$ or more than the patient's baseline creatinine level.

  • A urine output of less than $0.5\,mL/kg/h$ for $6$ consecutive hours.

• Early Diagnostic Considerations:

  • Immediately following a kidney injury, blood urea nitrogen (BUN) and serum creatinine levels may initially remain within normal ranges.

  • Decreased urine production (oliguria) may serve as the sole early clinical sign of kidney injury.

• Prognostic Correlation:

  • The duration of oliguria or anuria correlates directly with poor recovery of baseline renal function.

  • Prolonged periods of absent or reduced urine output decrease the likelihood that the patient will return to full baseline renal function.

Classification and Etiology of Acute Kidney Injury

• Pre-Renal AKI:

  • Definition: An adaptive physiological response to severe volume depletion and systemic hypotension in the presence of structurally intact nephrons. The primary impairment occurs prior to reaching the kidney.

  • Prevalence: Represents the most common cause of acute kidney injury.

  • Etiologies and Underlying Causes:

  • Volume Loss:

    • Renal losses: Diuretic overuse, polyuria.

    • Gastrointestinal losses: Severe vomiting, diarrhea.

    • Cutaneous losses: Severe burns.

    • Hemorrhage.

    • Pancreatitis.

  • Decreased Cardiac Output:

    • Heart failure.

    • Pulmonary embolism (PE).

    • Acute myocardial infarction (MI).

    • Severe valvular heart disease.

  • Systemic Vasodilation:

    • Sepsis.

    • Anaphylaxis.

    • Anesthetic agents.

    • Drug overdoses.

  • Afferent Arterial Vasoconstriction:

    • Hypercalcemia.

    • Pharmacological agents: Nonsteroidal anti-inflammatory drugs (NSAIDs), Amphotericin B, Norepinephrine, radiocontrast dye agents.

    • Hepatorenal syndrome.

  • Reduced Effective Arterial Blood Volume:

    • Hypoalbuminemia.

    • Heart failure.

    • Liver failure.

    • Sepsis.

• Intrinsic (Intra-Renal) AKI:

  • Definition: Structural injury inside the renal parenchyma occurring in response to cytotoxic agents, ischemia, or inflammatory insults, resulting in structural and functional damage to the kidney organ itself.

  • Hallmark Feature: Structural damage to the kidney parenchyma.

  • Etiologies and Underlying Causes:

  • Vascular Causes:

    • Renal artery obstruction (thrombus, arterial dissection, vasculitis).

    • Renal vein obstruction (thrombosis).

    • Malignant hypertension.

    • Scleroderma renal crisis.

    • Transplant rejection.

  • Glomerular Causes:

    • Anti-glomerular basement membrane (GBM) disease (Goodpasture syndrome).

    • Anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis.

    • Immune complex glomerulonephritis.

  • Cytotoxic Etiologies:

    • Rhabdomyolysis.

    • Intravascular hemolysis.

    • Intra-tubular crystal formation (Tumor lysis syndrome, seizures, ethylene glycol poisoning, megadoses of Vitamin C, acyclovir, methotrexate).

    • Nephrotoxic medications: Aminoglycosides, Lithium, Amphotericin B, radiocontrast agents.

  • Interstitial Causes:

    • Drug-induced acute interstitial nephritis: Penicillin, cephalosporins, NSAIDs.

    • Renal infections: Pyelonephritis.

    • Systemic illnesses: Systemic lupus erythematosus (SLE), lymphoma, leukemia.

• Post-Renal AKI:

  • Definition: Mechanical obstruction of urine passage anywhere along the urinary collecting system—including the renal pelvis, ureters, bladder, or urethra—resulting in obstructive uropathy.

  • Etiologies and Underlying Causes:

  • Collecting System / Ureteral Obstruction:

    • Nephrolithiasis / urolithiasis (kidney stones).

    • Strictures.

    • Retroperitoneal fibrosis.

    • Pelvic tumors, uterine fibroids.

    • Inadvertent ureteral ligation during pelvic surgical procedures.

    • Mechanical blockages such as a kinked urinary catheter.

  • Bladder Neck Obstruction:

    • Benign prostatic hypertrophy (BPH).

    • Prostate cancer.

    • Hemorrhage with blood clot retention.

    • Bladder tumors.

  • Urethral Obstruction:

    • Urethral strictures, urethral tumors.

  • Intra-Tubular Obstruction:

    • Distal obstruction resulting from tubular crystal accumulation.

Compensatory Mechanisms and Nursing Safety Habits in AKI

• Physiological Compensatory Pathways:

  • In response to pre-renal and post-renal pathology, the kidney attempts to maintain perfusion via three compensatory pathways:

  • Constriction of renal blood vessels.

  • Activation of the Renin-Angiotensin-Aldosterone System (RAAS).

  • Release of Antidiuretic Hormone (ADH).

  • Impact: While these mechanisms temporarily maintain perfusion, they impair urine elimination, resulting in oliguria (defined as urine output less than $400\,mL/day$) and azotemia (buildup of nitrogenous waste products in the blood).

• Reversibility:

  • Timely identification and removal of the underlying cause of AKI is essential to prevent permanent progression to end-stage renal disease and avoid lifelong reliance on renal replacement therapy.

• Critical Nursing Safety Habit:

  • Always evaluate perfusion parameters, review ordered medications, and check the physical patency of urinary drainage equipment (e.g., verifying that a Foley catheter is not kinked or obstructed) prior to assuming that the kidneys have structurally failed.

Clinical Assessment and Diagnostic Evaluation of AKI

• Health and Medication History:

  • Review renal history, recent trauma, surgical procedures, and active or recent systemic infections.

  • Obtain a detailed drug history, identifying current or recent exposure to nephrotoxic agents.

  • Document recent radiological examinations requiring intravenous contrast dye.

  • Identify comorbidities (e.g., diabetes mellitus, heart failure, chronic hypertension).

  • Screen for acute intercurrent illnesses (e.g., influenza, upper respiratory infections) and adverse drug reactions.

  • Assess cardiovascular parameters; trace causes of hypotension to determine systemic intravascular volume loss.

  • Inquire about urinary symptoms: difficulty initiating voiding, dysuria, diminished urine stream force, and nocturia.

• Physical Assessment:

  • Urine Output: Measure hourly urine output in post-surgical patients until clinically stable. Promptly report any sustained decline in output.

  • Fluid Overload Assessment: Monitor for signs of fluid retention secondary to impaired elimination:

  • Adventitious lung sounds (wet crackles).

  • Dyspnea and decreased oxygen saturation levels.

  • Dependent peripheral edema.

  • Hemodynamic & Perfusion Signs: Compare baseline vital signs to identify hypoperfusion:

  • Mean Arterial Pressure (MAP) monitoring.

  • Tachycardia and thready peripheral pulses.

  • Decreased level of consciousness (LOC).

• Laboratory Diagnostics:

  • Complete Blood Count (CBC): Evaluate Hemoglobin and Hematocrit (H&H) to estimate intravascular blood volume.

  • Serum Biochemistries: Monitor BUN, serum creatinine, and serum potassium levels.

  • Urinalysis with Microscopic Examination:

  • Specific gravity: Differentiates dilute urine from concentrated urine.

  • Microscopic sediment examination.

  • Urine Electrolytes: Urine sodium testing to assess tubular concentrating capacity and differentiate pre-renal from intrinsic injury.

• Diagnostic Imaging and Advanced Diagnostics:

  • Renal Ultrasonography: Non-invasive tool used to evaluate pre-existing kidney structural disease and identify mechanical obstructions in the urinary collecting system.

  • Doppler Ultrasonography: Evaluates the presence and characteristics of renal blood flow. Useful in diagnosing renovascular disease, thromboembolism, or hepatorenal syndrome (noted by increased resistive indices). Has limited utility in distinguishing pre-renal from intra-renal AKI because renal blood flow is diminished in both conditions.

  • Nuclear Scanning (Radionuclide Imaging): Assesses renal perfusion and tubular function. Value is limited during active pre-renal or intra-renal AKI due to delayed excretion of the radionuclide isotope through damaged renal tubules.

  • Renal Biopsy:

  • Indicated to identify specific intra-renal mechanisms when findings will directly alter clinical management (e.g., initiating high-dose immunosuppressive therapy).

  • Indicated during prolonged non-recovery of renal function to establish prognosis and formulate long-term plans.

  • Diagnostic Value: In up to $40\%$ of cases, renal biopsy results demonstrate an unexpected clinical diagnosis.

Medical and Nursing Management of Acute Kidney Injury

• Hemodynamic and Fluid Management:

  • Prevent systemic hypotension.

  • Maintain Mean Arterial Pressure (MAP) greater than $65\,mmHg$ (with target goals approaching $80\,mmHg$ in specific clinical scenarios).

  • Monitor daily weights, peripheral edema, and cumulative fluid balances.

  • Patients exhibiting positive fluid balance with volume overload may require diuretic therapy or fluid restriction.

  • Fluid Challenge Protocols: May be executed to enhance kidney perfusion; requires cautious administration and continuous monitoring for volume overload in patients with pre-existing pulmonary or cardiac disease.

• Medication Safety and Dose Titration:

  • Reduce exposure to nephrotoxic agents.

  • Titrate drug dosages according to fluctuating renal clearance levels.

  • Evaluate hepatic versus renal metabolic routes for prescribed drugs to prevent toxic drug accumulation.

  • Monitor therapeutic serum drug levels and immediately report elevated levels.

  • Coordinate with radiology teams to minimize radiocontrast media doses or utilize alternative diagnostic imaging modalities.

  • Diuretic Therapy Note: Loop diuretics are administered to promote fluid elimination and treat volume overload, but they do not preserve or restore intrinsic renal function.

• Pathophysiology of Non-Oliguric / Polyuric AKI:

  • AKI does not always present with oliguria.

  • Renal inflammatory responses can impair glomerular basement membrane permeability, allowing serum proteins to filter into the renal tubule.

  • Intra-tubular protein draws fluid into the filtrate via osmotic pressure, causing polyuria.

  • Polyuria leads to rapid intravascular volume depletion, hypovolemia, and significant electrolyte losses (specifically potassium and phosphorus depletion), requiring diligent IV and oral electrolyte replacement.

• Nutritional Support:

  • AKI induces hypercatabolism (rapid protein breakdown) that correlates with the severity of azotemia and uremia.

  • Consult a registered dietitian to establish individualized caloric and protein targets to preserve lean body mass.

  • Dietary salt and fluid restrictions are implemented to prevent volume overload.

  • Restrict dietary potassium and phosphorus during oliguric phases based on serum electrolyte monitoring.

  • In the polyuric recovery phase, potassium and phosphorus levels drop, necessitating dietary supplementation or intravenous electrolyte replacement.

  • Provide oral nutritional supplements or enteral nutrition support for patients with poor oral intake.

• Post-Hospital Discharge Care:

  • Outpatient monitoring requires routine follow-up with a nephrologist and primary care provider.

  • Serial lab testing (BUN, creatinine, electrolytes) to monitor recovery of renal function.

  • Instruct patients to maintain daily weight logs, track urine output, and monitor fluid balance.

  • Approximately $10\%$ of patients surviving AKI develop permanent ESRD, requiring long-term renal replacement therapy.

Chronic Kidney Disease (CKD): Pathophysiology and Manifestations

• Definition and Duration:

  • Chronic Kidney Disease (also termed chronic renal failure) is a progressive, irreversible loss of kidney function lasting longer than $3$ months.

  • Encompasses a continuum from mild kidney damage at risk for progression to complete kidney failure.

• Core Clinical Concepts:

  • Azotemia: The metabolic accumulation of nitrogenous waste products (BUN and creatinine) in the circulating blood volume.

  • Uremia: The systemic toxic clinical syndrome resulting from severe azotemia, affecting every major organ system.

  • Uremic Manifestations: Metallic taste in the mouth, anorexia, nausea, vomiting, muscle cramps, fatigue, lethargy, dyspnea, paresthesias, and uremic frost on the skin.

• Comparison Between AKI and CKD:

  • Onset:

  • AKI: Sudden (hours to days).

  • CKD: Gradual and progressive (minimum duration of $3$ months).

  • Nephron Involvement:

  • AKI: Affects $50\%$ to $95\%$ of nephrons acutely.

  • CKD: Varies by stage; clinical symptoms appear after a $75\%$ nephron loss; end-stage status involves $90\%$ to $95\%$ loss.

  • Duration and Reversibility:

  • AKI: Duration varies; full recovery to baseline is possible ($10\%$ to $20\%$ progress to chronic renal failure).

  • CKD: Permanent and irreversible progression requiring permanent lifestyle and medical modifications.

  • Prognosis:

  • AKI: Good prognosis if kidney function returns to baseline; guarded if renal replacement therapy is prolonged.

  • CKD: Dependent on GFR stage; ESRD is fatal without dialysis or kidney transplantation; reduced overall lifespan.

Staging of Chronic Kidney Disease (GFR and Albuminuria Categories)

• Stage 1 CKD:

  • Glomerular Filtration Rate (GFR): Normal or increased, $\ge 90\,mL/min/1.73\,m^2$, accompanied by structural or laboratory evidence of kidney damage.

  • Clinical Features: Asymptomatic. Identified via elevated serum creatinine or urea, microalbuminuria, hematuria, structural anomalies on imaging (MRI, CT, ultrasound), or a positive family history of autosomal dominant polycystic kidney disease.

  • Management: Screen for albuminuria and monitor serum creatinine levels, optimize blood pressure control, achieve glycemic control in diabetes, encourage a healthy lifestyle and regular exercise, and review routine medications.

• Stage 2 CKD:

  • GFR: Mildly decreased, $60 - 89\,mL/min/1.73\,m^2$.

  • Clinical Features: Persistent albuminuria, microscopic hematuria, structural changes visible on imaging scans, subtle increases in urine output that increase the risk for dehydration.

  • Management: Focus on risk factor reduction, strict blood pressure control, lifestyle modifications, and monitoring for disease progression.

• Stage 3 CKD (Divided into 3A and 3B due to differing risk and management profiles):

  • Stage 3A GFR: Moderately decreased, $45 - 59\,mL/min/1.73\,m^2$

  • Stage 3B GFR: Moderately to severely decreased, $30 - 44\,mL/min/1.73\,m^2$

  • Clinical Features: Accumulation of nitrogenous wastes begins to trigger uremic complications: hypertension, secondary anemia, early metabolic bone disease, generalized fatigue, fluid retention, extremity edema, dyspnea, urine appearance changes (foamy, dark orange, brown tea-colored, or hematuric red urine), alterations in urinary volume, lumbar/flank kidney pain, sleep disturbances secondary to nocturnal muscle cramps or restless legs syndrome.

  • Management: Interventions aimed at delaying progression: dietary restrictions, antihypertensive adjustments, glycemic management, serial lab monitoring, and dosage adjustments for renal-cleared medications.

• Stage 4 CKD:

  • GFR: Severely decreased, $15 - 29\,mL/min/1.73\,m^2$

  • Clinical Features: Severe uremic toxic symptoms: persistent nausea, vomiting, anorexia, bad breath (uremic fetor), dysgeusia (metallic taste), difficulty concentrating, cognitive decline, peripheral neuropathy (numbness and stocking-glove paresthesias in fingers and toes), severe anemia, worsening cardiovascular disease.

  • Management: Preparation for renal replacement therapy (RRT). Clinical discussions regarding hemodialysis, peritoneal dialysis, and kidney transplantation evaluation (preferred surgical treatment).

• Stage 5 CKD (End-Stage Renal Disease / ESRD):

  • GFR: Severe renal failure, $< 15\,mL/min/1.73\,m^2$

  • Clinical Features: Systemic toxic failure: loss of appetite, intractable nausea and vomiting, headaches, severe fatigue, inability to concentrate, severe intractable pruritus, oliguria or complete anuria, severe fluid retention (periorbital and ankle edema), muscle cramping, skin hyperpigmentation, general severe ill feeling (malaise).

  • Management: Lifelong dialysis (hemodialysis or peritoneal dialysis) or kidney transplantation. Dialysis initiation resolves metabolic toxicity and improves general symptom burden.

Systemic Effects and Multi-Organ Complications of CKD

• Metabolic Alterations:

  • Accumulation of serum creatinine and urea.

  • Sodium Balance:

  • Early Stage: Hyponatremia risk due to a reduced number of functional nephrons reabsorbing sodium.

  • Late Stage: Sodium retention occurs as urine production declines, causing hypernatremia, intravascular fluid expansion, severe hypertension, and peripheral edema.

  • Potassium Balance:

  • Hyperkalemia develops in advanced stages due to impaired distal tubular excretion.

  • Elevated potassium levels precipitate life-threatening cardiac dysrhythmias, necessitating strict dietary restrictions and avoidance of potassium-sparing drugs.

• Acid-Base Disturbances:

  • Progressive nephron loss decreases renal hydrogen ion excretion, reduces renal ammonium production, and impairs bicarbonate ($HCO_3^-$) reabsorption.

  • Accumulation of metabolic acids results in uncompensated Metabolic Acidosis.

  • Respiratory Compensation: Respiratory system increases rate and depth of ventilation to eliminate excess carbon dioxide ($CO_2$), manifesting clinically as Kussmaul respirations.

• Mineral and Bone Disorder (CKD-MBD):

  • Reduced phosphate excretion by damaged kidneys leads to hyperphosphatemia.

  • Excess serum phosphate binds directly to ionized calcium, causing secondary hypocalcemia.

  • Hypocalcemia stimulates the parathyroid glands to secrete excessive Parathyroid Hormone (PTH).

  • Elevated PTH triggers osteoclastic activity, pulling calcium out of the skeletal system, resulting in bone demineralization, osteodystrophy, bone pain, compaction of vertebrae, and pathological fractures.

  • Damaged kidneys fail to perform final activation of Vitamin D, preventing adequate GI calcium absorption.

  • Metastatic Calcification: Precipitated calcium-phosphate microcrystals deposit throughout extra-skeletal tissues (blood vessels, heart, lungs, joints, eyes, and brain), causing vascular stiffness and calciphylaxis.

• Cardiovascular Complications:

  • Renin-Mediated Hypertension: Ischemic or damaged kidneys hyper-secrete renin, driving excessive RAAS activation, resulting in severe hypertension that increases risks for myocardial infarction, left ventricular hypertrophy, congestive heart failure, and stroke.

  • Renal Anemia: Impaired synthesis of Erythropoietin (EPO) by renal peritubular cells reduces bone marrow erythrocyte production. Reduced red cell mass decreases tissue oxygen delivery, forcing the heart to increase cardiac output, precipitating heart failure and angina.

  • Uremic Pericarditis: Accumulation of metabolic uremic toxins causes pericardial membrane inflammation (visceral and parietal layers). Cardinal symptom is chest pain, accompanied by pericardial friction rub, fever, dyspnea, and tachycardia.

• Hematologic and Immunologic Alterations:

  • Uremia impairs white blood cell function, suppressing immune responses and predisposing patients to severe infections (e.g., pneumococcal pneumonia).

  • Coexisting deficiencies in iron and folic acid, combined with uremia-induced platelet dysfunction, increase bleeding risks (petechiae, purpura, gastrointestinal bleeding).

• Gastrointestinal Manifestations:

  • Uremic Fetor: Fishy or ammonia-like breath odor caused by urease-producing oral bacteria hydrolyzing elevated salivary urea into ammonia.

  • Uremic Stomatitis: Coated tongue, painful oral mucosal ulcerations, dysgeusia (metallic taste), and burning sensation.

  • GI Symptoms: Anorexia, nausea, vomiting, intractable hiccups, peptic ulcer disease, and uremic diarrhea.

• Integumentary and Neurologic Changes:

  • Integumentary: Pallor or sallow yellow-brown skin pigmentation (cutaneous deposition of urochrome pigments), severe dry skin (xerosis), decreased skin turgor, severe pruritus, and uremic frost (white urea crystals deposited on the skin following sweat evaporation).

  • Neurologic: Uremic encephalopathy (lethargy, seizures, coma), cognitive impairment, altered mental status, peripheral neuropathy presenting in a symmetric glove-and-stocking distribution.

Comprehensive Assessment and Diagnostic Workup for CKD

• Clinical History:

  • Record baseline demographics: age, gender, height, and weight.

  • Monitor weight changes: single-day weight gains exceeding $2\,lbs$ overnight or $5\,lbs$ in a week reflect fluid retention rather than caloric intake.

  • Screen for medical risk factors: diabetes mellitus, persistent hypertension, autoimmune illnesses, polycystic kidney disease.

  • Review dietary intake, medication usage (prescription, over-the-counter, supplements), and history of GI disturbances (metallic taste, hiccups, nausea).

  • Characterize voiding patterns: urine color, daily output volume, presence of sediment, odor, or diminished force of stream.

• Targeted Physical Examination:

  • Neurologic: Level of consciousness, signs of encephalopathy, peripheral sensory perception in extremities.

  • Cardiovascular: Blood pressure, apical pulse rate/rhythm, extra heart sounds ($S_3$ or $S_4$), jugular venous distension (JVD), peripheral edema.

  • Respiratory: Breath odor, respiratory depth/rate (Kussmaul breathing), adventitious crackles at pulmonary bases.

  • Hematologic: Skin pallor, ecchymosis, petechiae, active mucosal bleeding.

  • Musculoskeletal: Spine tenderness, vertebral compaction, joint swelling, fracture risk.

  • Integumentary: Skin turgor, presence of uremic frost, excoriations secondary to pruritus.

• Diagnostic Laboratory and Imaging Evaluation:

  • CBC: Detects normocytic, normochromic anemia (low hemoglobin/hematocrit) and altered platelet indices.

  • Basic Metabolic Panel (BMP): Evaluates BUN, serum creatinine, hyperkalemia, hyperphosphatemia, hypocalcemia, and decreased bicarbonate ($HCO_3^-$) levels.

  • Serum Albumin: Detects hypoalbuminemia stemming from urinary protein loss or severe hypercatabolic protein-calorie malnutrition.

  • Lipid Profile: Screen for hyperlipidemia given the elevated risk for accelerated cardiovascular disease.

  • Urinalysis: Evaluates protein excretion (proteinuria, albuminuria), micro-hematuria, specific gravity, and renal cast formation.

  • Imaging Studies: Plain renal X-rays to assess gross kidney dimensions; renal ultrasound or CT scans to rule out structural urinary tract obstruction.

Interventions and Nursing Management Priorities in CKD

• Fluid Volume Management:

  • Monitor daily weights using the same scale at the same time each day.

  • Instruct patients to report weight gains greater than $2\,lbs$ overnight or $5\,lbs$ in a $7\text{-day}$ period.

  • For hemodialysis patients, target interdialytic weight gains to no more than $3\,lbs$ between scheduled dialysis sessions.

  • Implement fluid restrictions and low-sodium dietary protocols.

  • Administer loop diuretics in mild-to-moderate CKD stages (ineffective in Stage 5 / ESRD).

• Emergency Management of Acute Pulmonary Edema:

  • Position the patient immediately in High Fowler's position.

  • Administer high-flow supplemental oxygen to maintain oxygen saturation ($O_2$ sat) greater than $92\%$

  • Administer prescribed intravenous loop diuretics (e.g., Furosemide).

  • Administer intravenous Morphine sulfate to decrease myocardial workload and venous return.

  • Administer intravenous Nitroglycerin to reduce pulmonary vascular pressure and left ventricular preload.

  • Continuous EKG, blood pressure, and vital sign monitoring.

• Cardiovascular Protection and Blood Pressure Control:

  • Target strict blood pressure control using prescribed antihypertensives:

  • Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs) in early stages to decrease intraglomerular pressure and proteinuria.

  • Diuretics, Calcium Channel Blockers, Alpha-blockers, Vasodilators.

  • Instruct patient on daily home blood pressure logging.

• Nutritional Therapy and Electrolyte Management:

  • Consult renal dietitians to calculate non-dialysis versus dialysis protein needs:

  • Non-dialysis CKD patients require restricted protein intake to slow uremic waste buildup.

  • Dialysis patients require increased dietary protein to compensate for amino acid and protein losses during dialysis sessions.

  • Restrict dietary sodium, potassium, and phosphorus intake.

  • Administer phosphate binders with meals to reduce GI absorption of phosphorus.

  • Provide targeted oral vitamin and mineral supplements (e.g., active Vitamin D analogs, iron formulations).

• Infection and Injury Prevention:

  • Maintain skin integrity and deliver strict aseptic care to vascular access sites (AV fistulas, grafts) or peritoneal dialysis catheters.

  • Utilize mechanical patient-lift equipment during transfers to minimize fracture risks associated with osteodystrophy and fragile bones.

• Energy Conservation and Psychosocial Support:

  • Administer Erythropoiesis-Stimulating Agents (ESAs) to maintain target hemoglobin levels around $10\,g/dL$, combined with parenteral or oral iron therapy.

  • Cluster nursing care to conserve patient energy.

  • Assess for anxiety, clinical depression, and social isolation; refer to psychiatric support services, social workers, and renal support groups.

Case Study Evaluation: Acute vs. Chronic Clinical Decision-Making

• Clinical Scenario Data:

  • Presentation: Patient experiencing severe vomiting and diarrhea.

  • Vital Signs: Blood pressure $88/54\,mmHg$, heart rate $112\,bpm$ (tachycardic).

  • Renal Findings: Urine output $20\,mL/h$ sustained over the past $7$ hours; serum creatinine increased from $0.9\,mg/dL$ to $1.3\,mg/dL$ over the past $36$ hours.

  • Physical Findings: Clear lung sounds, dry oral mucous membranes.

• Clinical Case Analysis Questions and Answers:

  • Criteria Confirmation: Does this clinical scenario meet criteria for Acute Kidney Injury? Yes. The serum creatinine increased by $0.4\,mg/dL$ (which exceeds the diagnostic threshold of $\ge 0.3\,mg/dL$ within $48$ hours), and the urine output ($20\,mL/h$) is less than $0.5\,mL/kg/h$ for more than $6$ consecutive hours.

  • Etiology Categorization: Which category of AKI is present? Pre-Renal AKI. Caused by intravascular volume depletion secondary to gastrointestinal fluid losses (vomiting and diarrhea), manifesting as systemic hypotension ($88/54\,mmHg$), compensatory tachycardia ($112\,bpm$), and mucosal dehydration.

  • First Clinical Priority: Immediate intravascular volume fluid resuscitation with IV fluids to restore renal arterial perfusion.

  • Plan Alteration Trigger: Development of pulmonary fluid overload signs (e.g., onset of bilateral basilar crackles, dyspnea, or reduced oxygen saturation) would mandate immediate cessation or reduction of fluid resuscitation protocols.

Patient Education and Self-Management Teachback Protocols

• Teachback Method Application:

  • Nursing education should utilize the teachback approach to verify patient comprehension regarding self-management plans.

• Targeted Patient Statements verifying Correct Understanding:

  • Monitoring: "I will track and log my daily body weight, blood pressure, symptoms, and urine appearance as instructed."

  • Medications: "I will consult my healthcare provider before taking any over-the-counter NSAIDs, herbal supplements, or new medications because my kidneys filter these substances."

  • Nutrition and Fluids: "My dietary and fluid plan is customized specifically to my personal lab results and treatment plan, rather than a generic kidney diet."

  • Symptom Escalation: "I will immediately report signs of physical swelling, decreased urine volume, shortness of breath, sudden muscle weakness, chest pain, or confusion."

  • Follow-Up Adherence: "I know exactly which laboratory appointments and physician visits are scheduled for my ongoing monitoring."